Hot Paths

Boston Scientific’s SEISMIQ 4CE succeeds in heart trial (BSX)

Boston Scientific Offers To Buy Guidant For $25 Billion

Joe Raedle/Getty Images News

Boston Scientific (BSX) announced on Tuesday that its SEISMIQ 4CE catheter, an intravascular lithotripsy device designed to fracture calcium within coronary arteries, has been successful in a clinical study for patients with calcified coronary artery disease.

The pivotal FRACTURE Investigational

Exit mobile version